[Palpebral edema secondary to treatment by a specific inhibitor of tyrosine kinase: Glivec. A case report].
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000037:antagonists & inhibitors; D001549:Benzamides; D001706:Biopsy; D003937:Diagnosis, Differential; D004487:Edema / Q000139:chemically induced* / Q000175:diagnosis / Q000473:pathology; D005141:Eyelid Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000473:pathology; D005143:Eyelids / Q000473:pathology; D005260:Female; D006801:Humans; D007049:Iatrogenic Disease; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects*; D013997:Time Factors
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases
OEdème palpébral secondaire au traitement par inhibiteur de la tyrosine kinase: Glivec. A propos d'une observation anatomo-clinique.